Join

Compare · ABT vs EGRX

ABT vs EGRX

Side-by-side comparison of Abbott Laboratories (ABT) and Eagle Pharmaceuticals Inc. (EGRX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ABT and EGRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • ABT is the larger of the two at $157.63B, about 268.9x EGRX ($586.2M).
  • Over the past year, ABT is down 32.2% and EGRX is up 0.0% - EGRX leads by 32.2 points.
  • ABT has hit the wire 6 times in the past 4 weeks while EGRX has been quiet.
  • ABT has more recent analyst coverage (25 ratings vs 2 for EGRX).
PerformanceABT-18.87%EGRX+0.00%
2026-02-12+0.00%2026-06-08
MetricABTEGRX
Company
Abbott Laboratories
Eagle Pharmaceuticals Inc.
Price
$90.44-0.69%
$2.12-40.84%
Market cap
$157.63B
$586.2M
1M return
+4.00%
+0.00%
1Y return
-32.20%
+0.00%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
2014
News (4w)
6
0
Recent ratings
25
2
ABT

Abbott Laboratories

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.

EGRX

Eagle Pharmaceuticals Inc.

Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Latest ABT

Latest EGRX